Sixth International Congress

Drug Therapy in HIV Infection


17-21 November, 2002
Glasgow, UK

Print this article
What to start with and what to include? Should compounds with noncross resistance profiles be preferentially used in initial or late therapy?

Julio Montaner1
Int Cong Drug Therapy HIV 2002 Nov 17-21;6:Abstract No. PL1.2

Abstract not available.

Presenting author: Julio Montaner

Download Conferences Abstracts

1 St Paul’s Hospital, University of British Columbia, Vancouver, Canada

2002-11-17
PL1-2

Copyright © 2002 - The Gardiner-Caldwell Group, Ltd.. All Rights Reserved. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Sixth International Congress on Drug Therapy in HIV Infection, c/o The Gardiner-Caldwell Group Ltd, part of The Thomson Corporation, Peakside House, Alder Court, Tytherington Business Park, Tytherington, Cheshire SK10 2XG, UK - Tel: +44 (0)1625 668000, Fax: +44 (0)1625 668121 Email: hiv6@gardiner-caldwell.com

This information is designed to support, not replace, the relationship that exists between you and your doctor. ©1980, 2005. AEGiS.